Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin B Sequential Itraconazole Therapy

NCT03827278 is registered in ClinicalTrials.gov with Guangxi Medical University as lead sponsor.

NCT NCT03827278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03827278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin B Sequential Itraconazole Therapy
Lead sponsor
Guangxi Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
December 30, 2018
Completion date
December 30, 2021
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

talaromyces in human immunodeficiency virus negative, to compare voriconazole and amphotericin sequential itraconazole therapy, to dynamically monitor the anti-interferon-γ autoantibodies